Bavarian Nordic Updates on Mpox Vaccine and Global Collaborations
![Bavarian Nordic Updates on Mpox Vaccine and Global Collaborations](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Bavarian Nordic's Vaccine Supply Initiatives for Mpox
COPENHAGEN, Denmark – Bavarian Nordic A/S (OMX: BAVA) provides a detailed update regarding its strategies to ensure a reliable supply of vaccines designed to address the ongoing mpox outbreak. The Africa Centers for Disease Control and Prevention (Africa CDC) has categorized this outbreak as a Public Health Emergency of Continental Security (PHECS). Following this, the World Health Organization (WHO) issued a declaration of mpox as a Public Health Emergency of International Concern (PHEIC).
Commitment to Equitable Vaccine Access
“Bavarian Nordic is collaborating closely with various stakeholders to guarantee equitable access to our mpox vaccine throughout the current PHECS and PHEIC,” stated Paul Chaplin, President & CEO of Bavarian Nordic. “We have established a robust partnership with Africa CDC, focusing not only on supply chains but also on enhancing our manufacturing capabilities within Africa. Our engagement with WHO aims to secure a regulatory pathway ensuring access for all nations, while simultaneously pursuing approval for adolescent usage and initiating clinical studies in Africa aimed at extending vaccination to children.”
History of Vaccine Distribution and Efficacy
In previous responses to global health crises, Bavarian Nordic successfully supplied over 15 million doses of the mpox vaccine to 76 countries during the mpox PHEIC of 2022/23. This provision of equitable vaccine access significantly contributed to controlling that outbreak, with clinical evidence showing high efficacy rates after one or two vaccinations, which notably reduced hospitalization rates among those infected.
Expansion of Vaccine Manufacturing Capacity
Since 2022, Bavarian Nordic has been proactive in building a vaccine inventory to address potential future mpox outbreaks. In light of recent developments, the company has also committed to increasing its manufacturing capacity to guarantee ongoing equitable access to the mpox vaccine. Bavarian Nordic has notified the Africa CDC that it can produce an additional 10 million doses by the end of 2025, alongside fulfilling existing orders, and anticipates supplying up to 2 million doses within the current year.
Focus on Youth Vaccination
Given that many current mpox cases in Africa involve individuals under 18, Bavarian Nordic has submitted clinical data to the EMA to support vaccine usage in adolescents aged 12–17. This data reflects findings from a collaborative clinical study conducted with the NIAID, part of the U.S. National Institutes of Health (NIH), involving over 300 participants aged 12-17 (NCT05740982). In addition, through a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), a clinical trial will soon commence to evaluate the immunogenicity and safety of the MVA-BN vaccine in children aged 2-12 years, further expanding its potential usage in younger demographics.
About Bavarian Nordic
Bavarian Nordic operates as a fully integrated vaccine company focused on protecting and saving lives through innovative vaccines. The company is recognized as a global leader in smallpox and mpox vaccines, supplying these vital products to governments aimed at enhancing public health preparedness. It boasts a diverse portfolio of vaccines developed for both travelers and endemic diseases. For additional information, please visit www.bavarian-nordic.com.
Frequently Asked Questions
1. What is Bavarian Nordic's role regarding the mpox vaccine?
Bavarian Nordic is committed to ensuring equitable access to its mpox vaccine by working closely with the Africa CDC and WHO to manage supply and enhance manufacturing capabilities.
2. How many doses of the mpox vaccine has Bavarian Nordic supplied?
The company has provided over 15 million doses of the mpox vaccine to more than 76 countries during the past outbreak.
3. What steps is Bavarian Nordic taking for future manufacturing?
Bavarian Nordic plans to increase its manufacturing capacity to produce an additional 10 million doses by the end of 2025, with up to 2 million doses available this year.
4. What age group is Bavarian Nordic focusing on for vaccinations?
The company recently submitted data to support vaccine use in adolescents aged 12–17 and is also conducting trials for children aged 2-12.
5. What diseases does Bavarian Nordic's portfolio cover?
Bavarian Nordic specializes in vaccines for smallpox, mpox, and provides vaccines for travelers and endemic diseases, enhancing global health preparedness.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/